Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Foreword
13 January 2021

Introducing Volume 10 of the Journal of Comparative Effectiveness Research

Author: Laura Dormer https://orcid.org/0000-0002-4868-8655 [email protected]Author Info & Affiliations
Volume 10, Number 1
https://doi.org/10.2217/cer-2020-0244
PDFFormats

Abstract

I am very pleased to welcome readers to the tenth volume of the Journal of Comparative Effectiveness Research (JCER). As in previous years, it is great to start off this issue with a look back on some of our article highlights from 2020, alongside some of this month’s key content.

References

1.
Lamvu G, Soliman AM, Johns B, Vora JB, Estes SJ. Impact of pain and non-pain comorbidities on opioid use in women with endometriosis. J. Comp. Eff. Res. 10(1), 17–27 (2020).
PubMed
Google Scholar
2.
Hoyler MM, Abramovitz MD, Ma X et al. Social determinants of health affect unplanned readmissions following acute myocardial infarction. J. Comp. Eff. Res. 10(1), 39–54 (2020).
Google Scholar
3.
Dosenovic S, Dujmic A, Nujic D et al. Reasons and factors associated with inconclusiveness of systematic reviews about interventions for neuropathic pain. J. Comp. Eff. Res. 10(1), 67–75 (2020).
PubMed
Google Scholar
4.
Swallow E, Patterson-Lomba O, Yin L et al. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J. Comp. Eff. Res. 9(4), 275–285 (2020).
PubMed
Google Scholar
5.
Mercuri E, Muntoni F, Osorio AN et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J. Comp. Eff. Res. 9(5), 341–360 (2020).
PubMed
Google Scholar
6.
Allan V, Ramagopalan SV, Mardekian J et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J. Comp. Eff. Res. 9(9), 603–614 (2020).
PubMed
Google Scholar
7.
Seewald MJ, Plumb JM, Gutierrez B et al. Strengthening pharma's contract with society: the value of trusted partnerships between pharma and healthcare facilitated by real-world data. J. Comp. Eff. Res. 9(3), 155–159 (2020).
PubMed
Google Scholar
8.
Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. J. Comp. Eff. Res. 9(3), 177–189 (2020).
PubMed
Google Scholar
9.
Olson M. Can real-world evidence save pharma US$1 billion per year? A framework for an integrated evidence generation strategy. J. Comp. Eff. Res. 9(2), 79–82 (2020).
PubMed
Google Scholar
10.
Serena TE, Yaakov R, Moore S et al. A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers. J. Comp. Eff. Res. 9(1), 23–34 (2020).
PubMed
Google Scholar
11.
Ramagopalan SV, Wasiak R. Life after COVID-19: R WE going to help? J. Comp. Eff. Res. 9(8), 525–526 (2020).
PubMed
Google Scholar
12.
Zambelli A, Pappagallo G, Marchetti P. Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis. J. Comp. Eff. Res. 9(6), 423–430 (2020).
PubMed
Google Scholar
13.
Mapel DW, Roberts MH, Davis J. Budesonide/formoterol therapy: effective and appropriate use in asthma and chronic obstructive pulmonary disease. J. Comp. Eff. Res. 9(4), 231–251 (2020).
PubMed
Google Scholar
|